Related Experiment Video

Updated: Feb 16, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

PD-L1 inhibitors in the pipeline: Promise and progress

Vito Vanella1, Lucia Festino1, Martina Strudel1

  • 1Melanoma, Cancer Immunotherapy and Innovative Therapies Unit - Istituto Nazionale Tumori Fondazione "G. Pascale," Napoli, Italy.

Oncoimmunology
|January 4, 2018
PubMed

Insights

Checkpoint inhibitors, like PD-L1 antibodies, improve survival in various cancers. Targeting PD-L1 shows promise for enhanced efficacy and reduced toxicity in cancer treatment.

Area of Science:

  • Oncology
  • Immunotherapy

Background:

  • Checkpoint inhibitors have transformed cancer treatment, improving survival rates for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck cancers.
  • Antibodies targeting Programmed Death-Ligand 1 (PD-L1), such as atezolizumab, avelumab, and durvalumab, are approved for treating various malignancies.

Purpose of the Study:

  • To review the efficacy and safety of anti-PD-L1 agents in cancer therapy.
  • To compare the benefits of targeting PD-L1 versus PD-1.

Main Methods:

  • Review of clinical studies and data on anti-PD-1/PD-L1 agents.
  • Comparative analysis of anti-PD-L1 drugs against anti-CTLA-4 therapies.

Main Results:

  • Anti-PD-1/PD-L1 agents demonstrate higher response rates and improved survival compared to anti-CTLA-4 drugs.
  • Anti-PD-L1 agents exhibit good efficacy and manageable toxicity across several tumor types.

Conclusions:

  • Targeting PD-L1 may offer theoretical advantages in efficacy and toxicity over PD-1 inhibition.
  • Anti-PD-L1 therapies represent a significant advancement in immuno-oncology, with broad applicability in cancer treatment.
Keywords:
AtezolizumabMerkel cell carcinomaPD-L1avelumabbladder cancerdurvalumabimmunotherapylung cancermelanoma

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.1K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
PD Controller: Design01:26

PD Controller: Design

In automotive engineering, car suspension systems often employ Proportional Derivative (PD) controllers to enhance performance. PD controllers are utilized to adjust the damping force in response to road conditions. A controller, acting as an amplifier with a constant gain, demonstrates proportional control, with output directly mirroring input.
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
673
Time-Domain Interpretation of PD Control01:07

Time-Domain Interpretation of PD Control

Proportional-Derivative (PD) control is a widely used control method in various engineering systems to enhance stability and performance. In a system with only proportional control, common issues include high maximum overshoot and oscillation, observed in both the error signal and its rate of change. This behavior can be divided into three distinct phases: initial overshoot, subsequent undershoot, and gradual stabilization.
Consider the example of control of motor torque. Initially, a positive...
411
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Frequency-Domain Interpretation of PD Control01:24

Frequency-Domain Interpretation of PD Control

Proportional-Derivative (PD) controllers are widely used in fan control systems to improve stability and performance. A fan control system can be effectively represented using a Bode plot to illustrate the impact of a PD controller through its transfer function. The Bode plot visually conveys how PD control modifies the fan's response across various frequencies, providing a frequency domain interpretation of the controller's behavior.
The proportional control gain, combined with the...
394
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K